As the first step to evaluate the efficacy of MitoQ and its combination with selpercatinib in RET-mutant tumor cells, we validated that mitochondrial enrichment of its functional moiety, ubiquinone, is critical for its growth inhibitory effects in TPC1 cells. The gene discussed is RET; the disease is neoplasm.